why choose us

First received: February 01, 2023

Clinical Trial: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Study Type: INTERVENTIONAL


Official Title: Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

Brief Summary: This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory).Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.Giving tegavivint may help control the disease.

Read more